Thursday, February 19, 2026

Latest

Canaccord: Aphria Estimated To Post 16% Increase In Recreational Sales In Q1 2021

This morning, Canaccord Genuity’s analyst Matt Bottomley released the firms fiscal first-quarter forecasts for Aphria Inc (TSX: APHA) (NASDAQ: APHA). They also reiterated their C$10 12-month price target and a speculative buy recommendation.

Bottomley’s headlines the note with “Expecting healthy Cdn recreational revenue growth and improved profitability.” Bottomley expects the same robust growth that Aphria reported in the previous quarter. Last quarter Aphria posted a ~27% quarter over quarter increase in their Canadian recreational sales. Bottomley believes that with two times the amount of stores opened and operating in Ontario, which Aphria has a #1 market share, it will be the primary driver in top-line success.

Bottomley further believes that recreational sales in this fiscal quarter will, “represent the company’s largest growth driver for the quarter after several notable market share gains in the prior period.” He forecasts a 20-25% increase in total consumption for Canadian recreational sales, and estimates that Aphria will achieve 16% quarter over quarter growth, which means Aphria’s gross recreational revenue is pegged at an estimated C$65.9 million.

Onto Aphria’s medical arm of the company, Bottomley’s says that fewer patients are booking appointments to renew prescriptions because of COVID-19. He expects medical revenue to be flat quarter over quarter and forecast C$8.6 million as the medical segment’s revenue.

Bottomley expects Aphria’s international revenue to drop by 2% this quarter, down to C$97.1 million as a result of seasonality.

Onto net revenues and gross margin, Bottomley estimates Aphria to have C$159 million in total net revenues, or up a modest 4.5% quarter over quarter. He says, “With some reliance on third-party purchased inputs in the prior period, we estimate that Aphria will see a modest ~50bp improvement in its consolidated adj. gross margin to 26.8% in FQ1/21, or ~C$42.6M.”

Lastly, Bottomley expects adjusted EBITDA to be healthy and come in at C$12.8 million, which is almost a 50% increase quarter over quarter. He believes that this is the case because of anticipated margins being higher and better OpEx spending.

Bottomley ends the note by saying, “the company should remain one of the only profitable LPs among market share leaders at this time.”

Aphria is scheduled to release first quarter financial results on October 15, 2020.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Eldorado Gold: The $3.8 Billion Foran Mining Acquisition

Silver Tiger’s $2.35B Silver Blueprint: Two Mines, One Perfect Metals Market

Gold Is At Records. Barrick Mining Is Printing Cash. The Stock Still Fell. | Q4 Earnings

Recommended

First Majestic Q4 2025: Record Revenue, Earnings, Annual Silver Output

Canadian Copper Plans 2,500 Metre Drill Program For 2026

Related News

Fortuna Silver: Q2 Production Gold Production Comes Up Short On BMO Estimates

Fortuna Silver Mines Inc. (TSX: FVI) yesterday reported its second-quarter production results. The company announced...

Tuesday, July 12, 2022, 12:36:00 PM

Cresco Labs: Canaccord Drops Price Target To $16

On November 11th, Cresco Labs (CSE: CL) reported its third-quarter financial results. The company reported...

Saturday, November 13, 2021, 01:04:00 PM

Nuvei Consensus Price Target Climbs $21 After Q2 Results Impress

On August 10, Nuvei Corporation (TSX: NVEI) reported its second quarter financial results. The company...

Sunday, August 15, 2021, 04:02:00 PM

Aphria Reports Independent Proxy Firms Approve Of Tilray Merger

Aphria Inc (TSX: APHA) (NASDAQ: APHA) is evidently looking to drum up shareholder support for...

Monday, April 5, 2021, 07:49:25 AM

CloudMD: Canaccord Reiterates $3.25 Price Target Following Acquisition

This morning, CloudMD Software & Services (TSXV: DOC) announced that they purchased Rx Infinity, an...

Wednesday, January 27, 2021, 04:01:00 PM